Glycoengineering specialist Glycoera AG is preparing to take its extracellular protein degrader constructs into the clinic in the treatment of autoimmune diseases, after closing a $130 million series B.
Glycoengineering specialist Glycoera AG is preparing to take its extracellular protein degrader constructs into the clinic in the treatment of autoimmune diseases, after closing a $130 million series B.
DUBLIN – As its name suggests, Glycoera AG aims to kickstart a new era in protein glycoengineering, and it has closed a CHF45 million (US$49 million) series A round to further its ambition of developing biologic drugs with defined glycosylation profiles that are an intrinsic aspect of their mechanisms.
